<DOC>
	<DOCNO>NCT00154310</DOCNO>
	<brief_summary>The purpose study ass whether calcineurin inhibitor ( CNI ) -free regimen enteric-coated mycophenolate sodium ( EC-MPS ) everolimus safe well-tolerated standard regimen contain enteric-coated mycophenolate sodium ( EC-MPS ) cyclosporine microemulsion , result well renal function .</brief_summary>
	<brief_title>Efficacy Safety Everolimus With Enteric-Coated Mycophenolate Sodium ( EC-MPS ) Cyclosporine Microemulsion-free Regimen Compared Standard Therapy de Novo Renal Transplant Patients</brief_title>
	<detailed_description />
	<mesh_term>Everolimus</mesh_term>
	<mesh_term>Sirolimus</mesh_term>
	<mesh_term>Mycophenolic Acid</mesh_term>
	<mesh_term>Prednisolone</mesh_term>
	<mesh_term>Immunosuppressive Agents</mesh_term>
	<mesh_term>Mycophenolate mofetil</mesh_term>
	<mesh_term>Cyclosporins</mesh_term>
	<mesh_term>Cyclosporine</mesh_term>
	<criteria>Inclusion Criteria : The follow inclusion criterion present BL 1 ( Screening visit prior transplantation ) : 1 . Males female , age 18 65 year 2 . Recipients de novo cadaveric , live unrelated living relate kidney transplant 3 . Females capable become pregnant must negative serum pregnancy test within 7 day prior BL 1 , require practice approve method birth control duration study period 6 week follow discontinuation study medication , even history infertility 4 . Patients willing able participate study write informed consent obtain Of patient include study BL 1 ( prior transplantation ) , continue randomize study period meet follow condition BL 2 , prior randomization : 5 . Patients immunosuppressive regimen ECMPS ( target dose ; 1440 mg/day , tolerate ; minimal dose : 720 mg/day ) , cyclosporine corticosteroid 6 . Patients actual serum creatinine = &lt; 3.0 mg/dl The following exclusion criterion must present BL 1 ( Screening visit prior transplantation ) : 1 . More one previous renal transplantation 2 . Multiorgan recipient ( e.g. , kidney pancreas ) previous transplant organ , different kidney 3 . Graft loss due immunological reason first year transplantation ( case secondary transplantation ) 4 . Patients recipient ABO incompatible transplant 5 . Patients historical current peak PRA &gt; 25 % 6 . Patients already exist antibody HLAtype receive transplant 7 . Females childbearing potential planning become pregnant , pregnant and/or lactating , unwilling use effective mean contraception Of patient include study BL 1 ( prior transplantation ) , meet one follow criterion BL 2 , prior randomization , continue randomize study period : 8 . Graft loss death 9 . Changes immunosuppressive regimen prior randomization due immunologic reason 10 . Patients suffer severe rejection ( &gt; = BANFF II acute rejection ) , recurrent acute rejection , steroid resistant acute rejection 11 . Proteinuria &gt; 1g/day Other protocoldefined exclusion criterion may apply .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>October 2013</verification_date>
	<keyword>Renal transplantation , everolimus , immunosuppressant , CNI-free</keyword>
</DOC>